SOUTH SAN FRANCISCO, Calif., Sept. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today presented data from a retrospective comparative analysis suggesting that treatment with ZYBRESTAT (fosbretabulin, or CA4P) confers a one-year survival benefit in patients with anaplastic thyroid cancer (ATC) compared to treatment with chemotherapy alone. The data derive from a comparison between the results of the company’s aggregate data from five independent prospective Phase 1 and Phase 2 trials using ZYBRESTAT to treat patients with ATC, including the FACT trial, and data from the 50-year experience in treating ATC patients at the Mayo Clinic, Rochester, MN (Mayo Group) from 1949-1999, published by Dr. Bryan McIver, one of the world’s leading experts in treating patients with ATC. OXiGENE’s FACT trial is the largest single, randomized, controlled, multi-center clinical trial ever conducted in ATC, and the Mayo studies comprise the largest retrospective review of the treatment outcomes in ATC conducted at a single institution. The FACT data were originally presented at the 2011 ASCO meeting by Dr. Julie Sosa from Yale Medical School, New Haven, CT.
